ReviewActa gastroenterologica Latinoamericana
[Precision Medicine in the Primary and Secondary Prevention of Gastric Cancer].
Review in Acta gastroenterologica Latinoamericana. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the most frequent cancers worldwide. It has a poor prognosis associated with late-stage diagnosis, that significantly decreases overall survival. This highlights the importance of prevention and early detection to improve the clinical course of patients. Prevention and early diagnosis of gastric cancer perfectly exemplify the model of precision medicine, a healthcare approach that seeks to place the burden more on the individual than on the general population. This requires not only a comprehensive knowledge of the disease but also the identification of individual factors and the understanding of genetic, molecular and environmental differences, which are key to the development of much more personalized treatment strategies. With this approach, in gastric cancer prevention the subject is always at the center, the measures focus directly on the individual and, secondarily, lead to the optimization of the use of resources. This review briefly discusses primary prevention strategies for gastric cancer based on detection and eradication of Helicobacter pylori and, on the other hand, describes some of the most promising biomarkers for the detection and diagnosis of early gastric cancer identified in blood, saliva, urine, feces, and gastric juice, all of which are components of potential secondary prevention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.